Trial Profile
A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma America
- 29 Jun 2020 According to Akebia Therapeutics Media Release, company has obtained manufacturing and marketing approval of vadadustat as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients by the Ministry of Health, Labour and Welfare in Japan on June 29, 2020.
- 05 May 2020 According to an Akebia Therapeutics media release, in collaboration with Mitsubishi Tanabe, the company is advancing key pre-commercial activities in support of the first regulatory approval of vadadustat expected in Japan this year.
- 23 Jul 2019 According to Akebia Therapeutics Media Release, the company announced that Mitsubishi Tanabe Pharma Corporation has submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labor and Welfare in Japan for manufacturing and marketing approval of vadadustat as a treatment for anemia due to chronic kidney disease (CKD) based on two pivotal studies and two additional Phase 3 single-arm studies.